Literature DB >> 31243333

Genomic and transcriptomic comparison of post-radiation versus sporadic sarcomas.

Tom Lesluyes1,2,3,4, Jessica Baud1,2, Gaëlle Pérot1,5, Céline Charon-Barra6, Axel You1,7, Isabelle Valo8, Céline Bazille9, Florence Mishellany10, Agnès Leroux11, Sophie Renard-Oldrini12, Philippe Terrier13, Axel Le Cesne14, Marick Laé15,16, Sophie Piperno-Neumann17, Sylvie Bonvalot18, Agnès Neuville5,19, Françoise Collin6, Philippe Maingon20, Jean-Michel Coindre2,5, Frédéric Chibon21,22.   

Abstract

Post-radiation sarcomas are rare secondary cancers arising from radiation therapies. To date, few genetic specificities have been described for such malignancies and the oncogenesis of sarcomas with complex genetics (both sporadic and post-radiation) remains largely misunderstood. We performed genomic and transcriptomic analyses on 77 post-radiation sarcomas using DNA-array and RNA sequencing. Consequently, we were able to investigate changes in copy number variations, transcriptome profiling, fusion gene expression, and mutational landscapes. We compare these data to a reference cohort of 93 sporadic sarcomas. At genomic level, similar chromosomal complexity was observed both in post-radiation and sporadic sarcomas with complex genetics. We found more frequent CDKN2A and CDKN2B (coding for p14/p16 and p15 proteins, respectively; at 9p21.3) losses in post-radiation (71%) than in sporadic tumors (39%; P = 6.92e-3). Among all detected fusion genes and punctual variations, few specificities were observed between these groups and such alterations are not able to drive a strong and specific oncogenesis. Recurrent MYC amplifications (96%) and KDR variants (8%) were detected in post-radiation angiosarcomas, in agreement with the literature. Transcriptomic analysis of such angiosarcomas revealed two distinct groups harboring different genomic imbalances (in particular gains of 17q24.2-17qter) with different clinical courses according to patient's vital status. Differential gene expression analysis permitted to focus on the immune response as a potential actor to tumor aggressiveness. Histochemistry validated a lower inflammation and lower immune infiltrate at tumor periphery for highly aggressive angiosarcomas. Our results provide new genomic and transcriptomic information about post-radiation sarcomas. The techniques we used (RNA-seq and DNA-arrays) did not highlight major differences in sarcomas with complex genetics depending on the radiation context, revealing similar patterns of transcriptomic profiles and chromosomal copy number variations. Additional characterizations, particularly whole genome sequencing, could measure changes in DNA following radiation therapy in such malignancies and may precise their oncogenesis.

Entities:  

Year:  2019        PMID: 31243333     DOI: 10.1038/s41379-019-0300-2

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  10 in total

Review 1.  Angiosarcomas: histology, immunohistochemistry and molecular insights with implications for differential diagnosis.

Authors:  Isidro Machado; Francisco Giner; Javier Lavernia; Julia Cruz; Víctor Traves; Celia Requena; Beatriz Llombart; José Antonio López-Guerrero; Antonio Llombart-Bosch
Journal:  Histol Histopathol       Date:  2020-09-04       Impact factor: 2.303

2.  Primary Mesenchymal Tumors of the Thyroid Gland: A Modern Retrospective Cohort Including the First Case of TFE3-Translocated Malignant Perivascular Epithelioid Cell Tumor (PEComa).

Authors:  Lingxin Zhang; Daniel Lubin; John H Sinard; Brendan C Dickson; Cristina R Antonescu; Hao Wu; Roheena Z Panni; Snjezana Dogan; Brian R Untch; Ronald A Ghossein; Bin Xu
Journal:  Head Neck Pathol       Date:  2022-02-26

Review 3.  Optimal Clinical Management and the Molecular Biology of Angiosarcomas.

Authors:  Tom Wei-Wu Chen; Jessica Burns; Robin L Jones; Paul H Huang
Journal:  Cancers (Basel)       Date:  2020-11-10       Impact factor: 6.639

4.  WWTR1(TAZ)-CAMTA1 gene fusion is sufficient to dysregulate YAP/TAZ signaling and drive epithelioid hemangioendothelioma tumorigenesis.

Authors:  Caleb N Seavey; Ajaybabu V Pobbati; Andrea Hallett; Shuang Ma; Jordan P Reynolds; Ryan Kanai; John M Lamar; Brian P Rubin
Journal:  Genes Dev       Date:  2021-03-25       Impact factor: 11.361

5.  cdev: a ground-truth based measure to evaluate RNA-seq normalization performance.

Authors:  Diem-Trang Tran; Matthew Might
Journal:  PeerJ       Date:  2021-10-04       Impact factor: 2.984

6.  A Case Report of Post-Radiotherapy c-MYC-Positive Angiosarcoma of the Breast.

Authors:  Edna Retter; Carol-Ann Benn; Christopher Maske; Bernardo Leon Rapoport
Journal:  Case Rep Oncol       Date:  2022-02-07

Review 7.  Application of Multi-Omics Approach in Sarcomas: A Tool for Studying Mechanism, Biomarkers, and Therapeutic Targets.

Authors:  Zijian Zou; Wei Sun; Yu Xu; Wanlin Liu; Jingqin Zhong; Xinyi Lin; Yong Chen
Journal:  Front Oncol       Date:  2022-07-08       Impact factor: 5.738

8.  Premalignant Conditions of Bone.

Authors:  Michael D Eckhoff; Matthew E Wells; Osvaldo Padilla; Elizabeth M Polfer; Christopher J Castagno; Ahmed M Thabet; Shaimaa Elzamly; Harry L Wilson; Rajiv Rajani
Journal:  J Am Acad Orthop Surg Glob Res Rev       Date:  2022-10-13

Review 9.  On the Relevance of Soft Tissue Sarcomas Metabolic Landscape Mapping.

Authors:  Miguel Esperança-Martins; Iola F Duarte; Mara Rodrigues; Joaquim Soares do Brito; Dolores López-Presa; Luís Costa; Isabel Fernandes; Sérgio Dias
Journal:  Int J Mol Sci       Date:  2022-09-28       Impact factor: 6.208

10.  Sarcomatous Meningioma: Diagnostic Pitfalls and the Utility of Molecular Testing.

Authors:  Calixto-Hope G Lucas; Patrick Devine; David A Solomon; Caterina Giannini; Guido Reifenberger; Sonika Dahiya; Dario Caccamo; Arie Perry
Journal:  J Neuropathol Exp Neurol       Date:  2021-09-10       Impact factor: 3.148

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.